Source comparison
CJC-1295 no DAC & Ipamorelin Side Effects Long Term Research Comparison
Mechanism GHRH receptor agonist. Stimulates pituitary GH release Ghrelin receptor agonist. Amplifies GH pulse amplitude Direct exogenous hormone replacement Peptide secretagogues work within physiological limits; synthetic GH bypasses feedback loops entirely C
This comparison does not assign a generated winner or score.
- Mechanism
- GHRH receptor agonist. Stimulates pituitary GH release
- Ghrelin receptor agonist. Amplifies GH pulse amplitude
- Direct exogenous hormone replacement
- Peptide secretagogues work within physiological limits; synthetic GH bypasses feedback loops entirely
- Cortisol Impact
- None at standard doses
- Minimal to none (10–15% experience transient elevation in weeks 1–8)
- Variable; some formulations elevate cortisol
- Ipamorelin's selectivity for GHS-R1a avoids cortisol spikes seen with older secretagogues
- Insulin Sensitivity
- Can induce mild resistance in 20–25% during prolonged use
- Same counter-regulatory effect as CJC-1295 no DAC
- Significant insulin resistance common at supraphysiological doses
- Monitor fasting glucose and HbA1c after 12 weeks; risk is dose-dependent
- Injection Site Reactions
- Mild erythema in 15–20%; resolves within 48 hours
- Similar frequency; less common with proper reconstitution technique
- Injection site lipohypertrophy documented with long-term use
- Rotate injection sites; use bacteriostatic water for reconstitution
- Receptor Desensitisation
- Documented after 16–20 weeks continuous use; reversible with 4-week washout
- Same desensitisation pattern; requires cycling
- Not applicable. Exogenous GH doesn't rely on receptor density
- Cycling every 12–16 weeks preserves long-term efficacy
- Long-Term Safety Data
- Limited formal trials beyond 90 days; observational data to 52 weeks shows benign profile
- Phase II data to 8 weeks; extensive off-label use suggests low risk
- Decades of clinical use; known risks include acromegaly, cardiomyopathy at excessive doses
- Peptide secretagogues lack the multi-year RCT data of synthetic GH but show no comparable serious adverse events in available literature